Novartis made a tender offer to acquire Regulus Therapeutics, filing the necessary documents with the SEC on June 25, 2025.

2 reports, 0 independent Updated Jun 25

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Novartis made a tender offer to acquire Regulus Therapeutics, filing the necessary documents with the SEC on June 25, 2025.

Who's involved

What this event is mainly about

Regulus Therapeutics SEC Novartis

Keep exploring

Part of

Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences. All 1 developments

The entities involved

Regulus Therapeutics
Biopharmaceutical company

Nothing else this week.
SEC
Slovak company
- DHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Mon 17:57
- The Fidelis Partnership is incorporating in Bermuda and filing for an initial public offering on the NYSE, with principal offices in London and a main office in Dublin.Mon 17:12
Novartis
Swiss-American multinational pharmaceutical corporation
- Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
- GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16

Related events

Coverage

Newest first; wire copies grouped

Jun 25Unknown outlet
Jun 23Unknown outlet